Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE The pathology finding in DLB is misfolded alpha-synuclein, the main component of Lewy bodies, propagating in the central nervous system. 30807982 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE GBA1 mutations reduce GCase activity, therefore promoting the aggregation of alpha-synuclein, a common neuropathological finding underlying Parkinson's disease (PD) and dementia with Lewy bodies. 28835999 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 GeneticVariation disease BEFREE Adult-onset neurodegenerative disorders, like Parkinson's disease (PD) and dementia with Lewy bodies (DLB), that share the accumulation of aggregated α-synuclein (αSyn<sub>agg</sub>) as their hallmark molecular pathology are collectively known as α-synucleinopathies. 30706414 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Biochemical and genetic evidence point towards alpha-synuclein aggregation as having a pivotal role in the onset and progression of several neurodegenerative disorders, including Parkinson's disease, multiple system atrophy and Lewy body dementia. 15790525 2005
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Moreover, alphaSYN fibrils are the major component of Lewy bodies, the neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies as well as of glial cytoplasmic inclusions in multiple system atrophy. 17932682 2008
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 GeneticVariation disease BEFREE To determine whether mutations in the genes for alpha-synuclein or beta-synuclein are responsible for dementia with Lewy bodies (DLB), a disorder closely related to Parkinson disease (PD). 15365127 2004
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Neuronal inclusions composed of α-synuclein (α-syn) characterize Parkinson's Disease (PD) and Dementia with Lewy bodies (DLB). 29716652 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Alpha-synuclein (α-syn) aggregation represents the pathological hallmark of α-synucleinopathies like Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). 28676095 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Function of α-synuclein and PINK1 in Lewy body dementia (Review). 25355138 2015
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE The conversion of α-synuclein into oligomers and fibrils is the hallmark of a range of neurodegenerative disorders including Parkinson's disease and dementia with Lewy bodies. 28671142 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Although its physiological function remains enigmatic, alpha-synuclein is implicated in movement disorders such as Parkinson's disease, multiple system atrophy, and in neurodegenerative diseases such as Dementia with Lewy bodies. 27334403 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 AlteredExpression disease BEFREE Interestingly, both PD and incidental Lewy body disease tissues showed 100% concordance for elevated levels of pathological α-synuclein seeding activity compared to control tissues. 31758740 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE In principle, two research approaches can be considered for the laboratory diagnosis of dementias: (i) the direct detection of disease specific protein like Abeta-peptide-oligomers in AD or alpha-synuclein-aggregates in DLB and (ii) the detection of surrogate markers that show an altered pattern of expression in early stages of the disease or are used in the differential diagnosis of other dementias and thus enable an exclusion diagnosis. 18374272 2008
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 GeneticVariation disease BEFREE These findings suggest that variants in all 3 members of the synuclein gene family, particularly SNCA and SNCG, affect the risk of developing DLBD and warrant further investigation in larger, pathologically defined data sets as well as clinically diagnosed Parkinson disease/dementia with Lewy bodies case-control series. 20697047 2010
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Aggregation of α-synuclein is a hallmark of Parkinson's disease and dementia with Lewy bodies. 29599149 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE The clinical features of postoperative delirium are similar to the core features of alpha synuclein-related cognitive disorders, such as Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 29630637 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Complementing the genetic evidence linking α-synuclein to PD and DLBD is the pathological finding that α-synuclein is a major constituent of Lewy bodies and Lewy neurites in the brains of patients with the common sporadic form of PD. 28213435 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 AlteredExpression disease BEFREE These observations suggest that sporadic DLB is not associated with overexpression of ASYN. 16319716 2005
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 GeneticVariation disease BEFREE The presynaptic protein alpha-synuclein is a prime suspect for contributing to Lewy pathology and clinical aspects of diseases, including Parkinson's disease, dementia with Lewy bodies, and a Lewy body variant of Alzheimer's disease. alpha-Synuclein accumulates in Lewy bodies and Lewy neurites, and two missense mutations (A53T and A30P) in the alpha-synuclein gene are genetically linked to rare familial forms of Parkinson's disease. 10934251 2000
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Lewy bodies and Lewy neurites composed primarily of α-synuclein characterize synucleinopathies including Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). 27956085 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE A failure of protein degradation may underpin Lewy body disease (LBD) where α-synuclein is assimilated into the pathognomic Lewy bodies and Lewy neurites. 29748975 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 GeneticVariation disease BEFREE Pathologically confirmed Lewy body disease clinically characterized by progressive parkinsonism and cognitive dysfunction is caused by SNCA duplication. 18413475 2008
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Emerging evidence implicates α-synuclein oligomers as potential culprits in the pathogenesis of Lewy body disease (LBD). 31685859 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 Biomarker disease BEFREE Brains from patients with Parkinson disease or dementia with Lewy bodies show aggregation of alpha-synuclein in precerebellar brainstem structures. 28439961 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.800 GeneticVariation disease BEFREE Consistent with the current view that dysfunction in the autophagy-lysosomal system may play a major role in the formation of axonal swellings, our studies showed globule, small axonal swellings, derived from transgenic mice expressing either human wild-type α-synuclein (αS-globule) or DLB-linked P123H β-synuclein (βS-globule), contained autophagosome-like membranes. 25996784 2015